View all trials
Are you a member? Sign in above to view additional information
  • Study title
    A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lympohoma kinase (ALK).
  • Protocol ID
    CLDK378X2103
  • Disease
    Disease Type Disease Subtype
  • Eligibility criteria
  • Study Status
    Open
  • Location(s)
    Royal Children's Hospital Melbourne
    • Centre Study Status:
      Open
    • Notes:
    Sydney Children's Hospital
    • Centre Study Status:
      Open
    • Notes:
  • Phase
    Phase 1
  • Study type
    Treatment
  • Diagnosis stage
    Relapse/refractory
  • Study open date
    13/11/2013
  • Study close date
    N/A
  • Study chair
  • Sponsor
    Novartis
Back to search results